Antigen-antibody interaction data | Immunoinformatics analysis

Dr. Yashwanth Subbannayya obtained his M.Sc. degree in Medical Biochemistry from Manipal University. He qualified the competitive CSIR-UGC National Eligibility Test and joined the Institute of Bioinformatics, Bangalore as a UGC Junior Research Fellow. As part of his Ph.D. work, he studied the molecular mechanisms of gastric cancer in clinical specimens using quantitative proteomic technologies. This study, the results of which were published in Cancer Biology and Therapy, yielded a novel therapeutic target for gastric cancer- CAMKK2. Further, he also studied the serum proteome of gastric cancer patients and developed assays for potential markers using the revolutionary multiple reaction monitoring approach. The results of this study were published in Journal of Proteomics. In addition to his research work, he also trained extensively in sample preparation for mass spectrometry, fractionation techniques and gained expertise in quantitative proteomic techniques and data analysis. In addition, he also trained extensively in various validation platforms including immunohistochemsitry, multiple reaction monitoring and Western blot. He has also worked as a curator for several biological databases including NetPath, Human Protein Reference Database (HPRD) and Breast cancer database. His work in various research projects have yielded him 23 publications either as lead author or co-author in peer reviewed journals. He is a reviewer for the journal Proteomics. Dr. Yashwanth Subbannayya joined the YU-IOB Center for Systems Biology and Molecular Medicine in June, 2015. During the initial period, his job consisted of assisting other personnel of the university in the establishment of YU-IOB Center for Systems Biology and Molecular Medicine. He was also involved in training of Ph.D. students in biological aspects. After the establishment of the center, he trained in cell culture techniques and metabolomics analysis. At YU-IOB CSBMM, he is studying the molecular mechanisms in various cancers including oral cancer. In addition, he is studying the molecular mechanisms as well as the metabolic constituents of traditional medicine formulations using mass spectrometry technologies. In June 2016, he convened the national symposium “Genomics in clinical practice: Future of precision medicine” held at Yenepoya University on June 1 and 2, 2016. The resource persons included 16 individuals from various academic organizations as well as industry. The symposium was attended by 218 participants from 24 institutions around India. He is a member of the Scientific Review Board of Yenepoya Research Centre where he facilitates timely scientific review of research projects.

Antigen-antibody interaction databases | Immunology system data analysis

Antibodies (Abs) are an important class of molecules used in research and increasingly as therapeutic agents to treat human diseases. Therapeutic antibodies have certain advantages over small molecules or other protein therapeutics, such as longer serum half‐lives, higher avidity and selectivity, and the ability to invoke desired immune responses. Antibody paratopes—the parts of antibodies that interact with the target antigen—can recognize almost any biomolecular target, with a large range of specificities and affinities. Knowledge of the structure of an antibody–antigen or antibody–receptor complex provides insight into how the antibody recognizes its binding partner and can guide the process of antibody design. To increase the amount of relevant binding data available for computational method validation some databases of antibody–antigen, antibody–effector, and antibody‐like protein complexes with known structures has been developped. A database enables computational benchmarking studies of existing methods and can thereby be used to drive improvements in modeling methodology

Source text:
(Sirin et al., 2016) AB-Bind: Antibody binding mutational database for computational affinity predictions. Protein Sci.